Shield Therapeutics (STX) - Fortified for growth

11:06 EST 19 Feb 2019 | Edison Investment Research

Edison Investment Research - Pharmaceuticals & healthcare - Shield Therapeutics: Shield Therapeutics is focused on the development and commercialisation of Feraccru, a CHMP-approved oral formulation of iron positioned for the treatment of iron deficiency (ID) with or without anaemia. In 2018, out-licensing Feraccru to Norgine re-established an active salesforce in core EU5 territories and provided Shield with a cash injection of £11m. Additional near-term revenue (royalties and milestones) is expected as Norgine continues rollout of Feraccru across Europe in 2020. In the US, we expect Feraccru approval in 2019. We value Shield at £178m or 153p/share.
ISIN: GB00BYV81293

Original Article: Shield Therapeutics (STX) - Fortified for growth


More From BioPortfolio on "Shield Therapeutics (STX) - Fortified for growth"

Quick Search


Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...